Journal article
Antisense '97: A roundtable on the state of the industry
Nature biotechnology, v 15(6), pp 519-524
01 Jun 1997
PMID: 9181572
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
The following article is excerpted from the transcript of a one-hour roundtable discussion that concluded Nature Biotechnology's conference ''Antisense 97: Targeting the Molecular Basis of Disease,'' May 1-2, 1997 in Cambridge, MA. The purpose of the roundtable was to allow both speakers and conference attendees to address what they saw as the critical issues that had arisen during the two-day meeting. The transcript has been edited to address the major themes emerging from that discussion: the impact of first-generation vs. second-generation antisense drugs, the need to encourage dissemination of high-quality data, the reasons for the lack of reproducibility of certain data, whether genotoxicity should be a more closely studied issue, and what future directions may be for the field.
Metrics
Details
- Title
- Antisense '97: A roundtable on the state of the industry
- Creators
- J WyngaardenJ PottsF CotterR R MartinViren MehtaF EcksteinA LevinB WeissL BlackR ColeS CrookeA KreigR Diasio
- Publication Details
- Nature biotechnology, v 15(6), pp 519-524
- Publisher
- Springer Nature
- Number of pages
- 6
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Pharmacology and Physiology
- Web of Science ID
- WOS:A1997XC77200025
- Scopus ID
- 2-s2.0-0030951966
- Other Identifier
- 991019169101904721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- Industry collaboration
- Domestic collaboration
- International collaboration
- Web of Science research areas
- Biotechnology & Applied Microbiology